VICTORIA, BC — /CNW/ — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) today announced that it has filed and obtained a receipt for a preliminary short form base… Read More
Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023 TORONTO, ON — Zucara Therapeutics Inc., (“Zucara” or the… Read More
VANCOUVER, BC — /CNW/ — Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today… Read More
Numinus has submitted a Clinical Trial Application (CTA) to Health Canada to enable MDMA-assisted therapy Experiential Opportunities for practitioners as part of an investigational Phase 1 clinical trial. If approved, Numinus… Read More
Investment further positions Canadian post-secondary institutions as world leaders Throughout Canada, universities spur innovation, support scientific discoveries and train tomorrow’s researchers and workers. To ensure Canada remains at the forefront… Read More
